India-based Glenmark Pharmaceuticals Inc.'s USA subsidiary, Thursday announced the launch of Clindamycin Phosphate Foam, 1 percent for the treatment of acne.
The company added that Clindamycin Phosphate Foam, 1 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam, 1 percent, of Mylan Pharmaceuticals Inc.
Notably, the Evoclin Foam, 1 percent market reported annual sales of approximately $5.8 million, according to IQVIA sales data for the 12-month period ending December 2024.
Thursday, Glenmark closed at INR 1,411.20, up 0.36 percent on the National Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.